March 9, 2015 — Corindus Vascular Robotics Inc. announced it has initiated a clinical trial of its CorPath System in peripheral vascular interventions. The study is currently enrolling patients at the Medical University of Graz in Graz, Austria, and is led by Prof. Marianne Brodmann, M.D., a leading researcher with the university’s Division of Angiology, in combination with Prof. Hannes Deutschmann, M.D., of the Medical University of Graz Department of Radiology, and study chairman, Ehtisham Mahmud, M.D., director, Sulpizio Cardiovascular Center-Medicine, UC San Diego.
“I routinely use the CorPath System in complex PCI [percutaneous coronary intervention] cases and it reduces my exposure to a significant amount of scatter radiation,” said Mahmud. “The value of precision and protection afforded to physicians performing PCI through robotic technology is considerable. As peripheral vascular procedures are lengthy and often complex, the ability to translate the effectiveness of robotic technology to peripheral interventions has tremendous potential to be of benefit to both patients and physicians.”
The trial is a prospective, single-arm, single-center study that will enroll up to 20 patients. Researchers participating in the study will assess the safety and effectiveness of the CorPath System in recanalizing lower extremity arterial blockages during peripheral angioplasty procedures.
“It was astonishing how easy it was to advance the guidewire and balloon catheter in a precise controlled manner in the superficial femoral artery,” said Brodmann. “The results of this trial can mean the extension of the CorPath System’s capabilities to a greater range of procedures to further transform care delivery in the cath lab.”
Developed by Corindus Vascular Robotics, the CorPath System is the first U.S. Food and Drug Administration (FDA)-cleared medical device to bring robotic-assisted precision to coronary angioplasty procedures. During the procedure, the interventional cardiologist sits in the radiation-shielded interventional cockpit and advances stents and guidewires with millimeter-by-millimeter precision.
The CorPath System is currently indicated in the United States for PCI only.
For more information: www.corindus.com
November 18, 2024 
